www.hull.hr www.hull.hr
Dobro došli na forum Hrvatske udruge leukemija i limfomi
 
 FAQFAQ   PretražnikPretražnik   ČlanstvoČlanstvo   Korisničke grupeKorisničke grupe   RegistracijaRegistracija 
 ProfilProfil   Privatne porukePrivatne poruke   LoginLogin 

Folikularni Non Hodgkins Limfom
Prethodna  1, 2, 3 ... 13, 14, 15
 
Započni novu temu   Odgovori na temu    www.hull.hr -> Dijagnoza
Prethodna tema :: Sljedeća tema  
Autor/ica Poruka
inn



Pridružen/a: 09. 11. 2010.
Postovi: 8

PostPostano: pon lis 03, 2011 1:44 pm    Naslov: Citiraj i odgovori

STK - nije me bilo neko vrjeme,
kako vidim prosli ste autotransplantaciju, strah te da se opustis potpuno razumem te , ali nedaj se...mislim da vreme radi za sve, tamo vamo cujem ponesta ili procitam ohrabrijuci vjesti da se vrlo intenzivni istrazuje limfom te da ce u skoro buduce imati nove pristupe pa i neke vakcine,,,,tako da nadajmo se na dobru samo da izdrzimo ...autotransplantacijama godine ljudi su bili u remisiji i to sa visi stupanj agresivnosti tako da kod vas trebalo bi da bude jos bolje....

kolko se ostaje u bolnici od pocetak do kraja ove intervencije???? znam da je sve relativno i zavisi mozda od vise faktora ali eto odprilike ili u vasem slucaju kako je bilo???

pozzz i zelim svako dobro svima vama...
[Vrh]
Korisnički profil Pošalji privatnu poruku
stk



Pridružen/a: 25. 08. 2009.
Postovi: 265
Lokacija: Zagreb

PostPostano: pet tra 13, 2012 3:25 pm    Naslov: Citiraj i odgovori

Evo nekih novosti koje sam iskopala na internetu. NIšta ne kužim (more or less), ali ako se nekome tko kuži nešto, da to objasniti po zdravoseljački bila bih zahvalna...pozdrav svima. stk



"...investigated a compound known as TL32711 (Birinapant), developed by TetraLogic Pharmaceuticals in Malvern, Pennsylvania. The compound works by blocking the process cells used to avoid death, he explains -- in other words, it inhibits the process that inhibits cell death. "TL32711 is like a double-negative. It inhibits the inhibitor, and therefore makes cells more sensitive to dying."

To test whether TL32711 works better in some types of lymphomas than others, Smith and his team added it to various lymphoma cells. Since compounds tend to work best when given in combination with other drugs, in some cells they added another compound known as TRAIL, which targets tumor cells.

The researchers found that some types of lymphoma appeared more vulnerable to the effects of TL32711, suggesting these patients should be the first to try the finished product in clinical trials. Specifically, they saw that follicular lymphoma cells and some types of diffuse large B cell lymphomas were more likely to die following treatment. Not surprisingly, adding TRAIL to the mix appeared to make TL32711 even more effective at killing lymphoma cells. "We saw the combination worked better than either one alone," says Smith.

Importantly, the researchers saw the cells didn't just die -- they died because of the action of the compounds, explains Smith. TL32711 works by enhancing cell death -- known formally as apoptosis -- and just before cells experience apoptosis, they activate proteins known as caspases. Sure enough, after exposure to the compounds, the level of active caspases increased, confirming the cells were undergoing more apoptosis. "This result confirms that the cells are dying the way they should when you add these compounds," says Smith.

TL32711 is not yet available in the clinic, says Smith, but already some clinical trials are enrolling patients to test its effects. He and his colleagues plan to continue to test the compound in animals, to get a better sense of how it should best be used in humans.

"We're getting a much better understanding of why lymphoma cells don't die," he adds. "We're starting to see drugs that hit different pathways in the cell. Our research is about trying to take the compounds that target this particular pathway forward in the most efficient way possible."

Dr. Smith's co-authors include Indira Joshi at Fox Chase Cancer Center, along with colleagues from TetraLogic Pharmaceuticals.

This work was supported in part by funding from TetraLogic Pharmaceuticals.
[Vrh]
Korisnički profil Pošalji privatnu poruku
Prethodni postovi:   
Započni novu temu   Odgovori na temu    www.hull.hr -> Dijagnoza Vremenska zona: GMT + 01:00.
Prethodna  1, 2, 3 ... 13, 14, 15
Stranica 15 / 15.

 
Forum(o)Bir:  
Ne možeš otvarati nove teme.
Ne možeš odgovarati na postove.
Ne možeš uređivati svoje postove.
Ne možeš izbrisati svoje postove.
Ne možeš glasovati u anketama.


Powered by phpBB © 2001, 2005 phpBB Group
HR (Cro) by Ančica Sečan